Comparison between preprandial vs. postprandial insulin aspart in patients with type 1 diabetes on insulin pump and real-time continuous glucose monitoring

What Was Tested

Researchers studied Insulin Aspart in this randomized controlled trial publication.

The objective was to compare glycemic control between preprandial and postprandial bolus administration (15 min before [PRE] or immediately after the meal [POST]) in patients with type 1 diabetes using insulin pump and real-time continuous glucose monitoring.

Who Took Part

By PubMed's age tags, the people studied were young adults, adults and middle-aged adults, both men and women.

Between September 2015 and February 2016, a single-centre, open randomized, 2-way crossover study of patients on bolus insulin aspart administration was conducted during two 14-day periods and according to 2 administration regimen schedules (PRE/POST or POST/PRE).

Inclusion criteria were as follows: patients with type 1 diabetes, ≥18 and ≤ 65 years old, treated with insulin aspart using a Medtronic® insulin pump and trained on functional insulin therapy.

How the Study Was Run

In design terms this was a randomized and crossover study.

The participants were allocated by chance, so the Insulin Aspart group and the comparison group should start out alike.

Each person switched between Insulin Aspart and the comparison at some point, usually with a gap in between.

Patients were randomly assigned to either regimen schedule.

At the beginning of each period, each patient was provided with a standardized high fat meal.

Secondary outcomes were time spent in hypo/eu/hyperglycemia, glycemic variability indices, and AUC during 4 hours after high fat meal calculated with continuous glucose monitoring data.

What Was Measured

The subject headings attached to it are Administration, Metronomic, Blood Glucose, Blood Glucose Self-Monitoring, Diabetes Mellitus, Type 1, Diet, High-Fat, Insulin and Insulin Aspart.

Author keywords: glycemic variability, postprandial glycemia, real-time continuous glucose monitoring and type 1 diabetes.

What This Means in Plain Language

The paper is a randomized and crossover study of Insulin Aspart.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2018 (Diabetes/metabolism research and reviews), a journal based in England.

More context: the Insulin Aspart compound page.